Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution

被引：0
|
作者：
Thomas Gerloff
机构：
[1] Charité University Medical Center,Institute of Clinical Pharmacology
[2] Humboldt University,undefined
来源：
Naunyn-Schmiedeberg's Archives of Pharmacology | 2004年 / 369卷
关键词：
Pharmacogenetics; Transmembrane transporters; Drug disposition; Polymorphisms; Blood tissue barriers; Uptake; Efflux;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Active transport across biological membranes has become a noticeable factor in the absorption, distribution, and excretion of an increasing number of drugs. Different transmembrane transport systems including organic anion transporters (OATP, solute carrier family SLC21A), organic cation transporters (OCT, SLC22A), dipeptide transporters (PEPT, SLC15A), nucleoside transporters (CNT, SLC28A), monocarboxylate carriers (MCT, SLC2A), and members of the large ATP-binding cassette family (ABC, SLC3A) are involved in drug disposition. Genetic polymorphisms in transport proteins frequently occur and contribute to interindividual differences in the efficacy and safety of pharmatherapy. Currently, the most advanced research has been done on P-glycoprotein (ABCB1, SLC3A1.201.1). Knowledge of this transporter indicates that haplotype analysis rather than association with single nucleotide polymorphisms (SNPs) provides the most appropriate interpretation of pharmacogenetic data from drug transporters. This review gives an overview and update on the pharmacological impact of genetic variants in transmembrane transporters.
引用
收藏
页码：69 / 77
页数：8
相关论文
共 37 条
  • [1] Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution
    Gerloff, T
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 (01) : 69 - 77
  • [2] Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution
    Thomas Gerloff
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369 (2) : 268 - 268
  • [3] The impact of xenobiotic metabolism and genetic Polymorphisms on male fertility
    Schuppe, HC
    Abel, J
    Schill, WB
    SKIN AND ENVIRONMENT - PERCEPTION AND PROTECTION, VOLS 1 AND 2, 2001, : 1005 - 1010
  • [4] Poly(L-lactide)-N-heterocyclic functionalised drug conjugates as drug carrier-systems: Synthesis, mechanistic and kinetics study
    Katiyar, Vimal
    Gupta, Arvind
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [5] Poly(L-lactide)-N-heterocyclic functionalised drug conjugates as drug carrier-systems: Synthesis, mechanistic, and kinetics study
    Katiyar, Vimal
    Mili, Medha
    Gupta, Arvind
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [6] Genetic Polymorphisms and Population Distribution: Phase I and Phase II Xenobiotic Enzymes: Implications of Health Assessments
    Ginsberg, G.
    Sonawane, B.
    Guyton, K.
    Johns, D.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2009, 50 (07) : 540 - 540
  • [7] Genetic polymorphisms in drug metabolizing enzymes -: impact on treatment with β-blockers
    Wuttke, H
    Rau, T
    Eschenhagen, T
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2004, 129 (15) : 831 - 835
  • [8] Impact of genetic polymorphisms of ABC transporter genes on the drug treatment
    Ieiri, I
    JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 88 : 47P - 47P
  • [9] Impact of Genetic Polymorphisms and Drug-Drug Interactions on Clopidogrel and Prasugrel Response Variability
    Ancrenaz, V.
    Daali, Y.
    Fontana, P.
    Besson, M.
    Samer, C.
    Dayer, P.
    Desmeules, J.
    CURRENT DRUG METABOLISM, 2010, 11 (08) : 667 - 677
  • [10] Parelectric spectroscopy of drug-carrier-systems - distribution of carrier masses or activation energies
    Sivaramakrishnan, R
    Kankate, L
    Niehus, H
    Kramer, KD
    BIOPHYSICAL CHEMISTRY, 2005, 114 (2-3) : 221 - 228
1234